These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36300887)

  • 1. Mutational profiling of circulating tumor DNA and clinical characteristics in lymphoma: Based on next generation sequencing.
    Hou Y; Zi J; Liu S; Ge Q; Ge Z
    Mol Carcinog; 2023 Feb; 62(2):200-209. PubMed ID: 36300887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
    Zhou LH; Feng YQ; Hu YX; Huang H
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):805-812. PubMed ID: 38049331
    [No Abstract]   [Full Text] [Related]  

  • 3. Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma.
    Guan T; Zhang M; Liu X; Li J; Xin B; Ren Y; Yang Y; Wang H; Zhao M; Huang Y; Guo X; Du J; Qian W; Su L
    Front Oncol; 2022; 12():1003957. PubMed ID: 36465410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
    Zhang S; Zhang T; Liu H; Zhao J; Zhou H; Su X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; He J; Wang X; Zhang H
    Br J Haematol; 2022 Feb; 196(3):617-628. PubMed ID: 34664256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
    Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
    Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
    Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
    J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.
    Scherer F; Kurtz DM; Newman AM; Stehr H; Craig AF; Esfahani MS; Lovejoy AF; Chabon JJ; Klass DM; Liu CL; Zhou L; Glover C; Visser BC; Poultsides GA; Advani RH; Maeda LS; Gupta NK; Levy R; Ohgami RS; Kunder CA; Diehn M; Alizadeh AA
    Sci Transl Med; 2016 Nov; 8(364):364ra155. PubMed ID: 27831904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy.
    Zou H; Liu W; Wang X; Wang Y; Wang C; Qiu C; Liu H; Shan D; Xie T; Huang W; Sui W; Yi S; An G; Xu Y; Ma T; Wang J; Qiu L; Zou D
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38443094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evaluation of gene mutation profiles by next-generation sequencing in diffuse large B-cell lymphoma.
    Özçalımlı A; Erdoğdu İH; Turgutkaya A; Yavaşoğlu İ; Döger FK; Bolaman AZ
    Int J Lab Hematol; 2023 Jun; 45(3):310-316. PubMed ID: 36576110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor DNA Reflects Histologic and Clinical Characteristics of Various Lymphoma Subtypes.
    Kim JJ; Kim HM; Kim H; Kim SJ; Lee ST; Choi JR; Shin S; Hwang DY
    Cancer Res Treat; 2024 Jan; 56(1):314-323. PubMed ID: 37475138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mutational Spectrum and Prognosis Analysis of Young Patients with Diffuse Large B-Cell Lymphoma Based on Next-Generation Sequencing].
    Lyu LY; Nie YL; Renaguli A; Qi XL; Muhebaier A; Zhai SS; An L; Mao M; Li Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):403-410. PubMed ID: 37096512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
    Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
    Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue-Matched IgH Gene Rearrangement of Circulating Tumor DNA Shows Significant Value in Predicting the Progression of Diffuse Large B Cell Lymphoma.
    Zhao K; Zheng X; Liu X; Liu T; Ke Z; Zhu F; Wen Q; Xin B; Li Q; Zhang L
    Oncologist; 2024 May; 29(5):e672-e680. PubMed ID: 38297976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor DNA in Lymphoma.
    Thiruvengadam SK; Zain J
    Curr Hematol Malig Rep; 2022 Dec; 17(6):298-305. PubMed ID: 36214943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma.
    Grønbaek K; Worm J; Ralfkiaer E; Ahrenkiel V; Hokland P; Guldberg P
    Blood; 2002 Aug; 100(4):1430-7. PubMed ID: 12149228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study.
    Rivas-Delgado A; Nadeu F; Enjuanes A; Casanueva-Eliceiry S; Mozas P; Magnano L; Castrejón de Anta N; Rovira J; Dlouhy I; Martín S; Osuna M; Rodríguez S; Simó M; Pinyol M; Baumann T; Beà S; Balagué O; Delgado J; Villamor N; Setoain X; Campo E; Giné E; López-Guillermo A
    Clin Cancer Res; 2021 Jan; 27(2):513-521. PubMed ID: 33122345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses.
    Todorovic Balint M; Jelicic J; Mihaljevic B; Kostic J; Stanic B; Balint B; Pejanovic N; Lucic B; Tosic N; Marjanovic I; Stojiljkovic M; Karan-Djurasevic T; Perisic O; Rakocevic G; Popovic M; Raicevic S; Bila J; Antic D; Andjelic B; Pavlovic S
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27164089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin's lymphoma.
    Bastos-Oreiro M; Suárez-González J; Andrés-Zayas C; Carrión NC; Moreno S; Carbonell D; Chicano M; Muñiz P; Sanz L; Diaz-Crespo FJ; Menarguez J; Diez-Martín JL; Buño I; Martínez-Laperche C
    Sci Rep; 2021 Nov; 11(1):22815. PubMed ID: 34819573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid biopsy in diffuse large B-cell lymphoma: utility in cell origin determination and survival prediction in Chinese patients.
    Li M; Ding N; Mi L; Shi Y; Du X; Yi Y; Yang L; Liu W; Zhu J
    Leuk Lymphoma; 2022 Mar; 63(3):608-617. PubMed ID: 34751093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
    Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
    Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.